1990—2019年江苏省非霍奇金淋巴瘤疾病负担研究

目的 分析1990—2019年江苏省非霍奇金淋巴瘤疾病负担变化情况，为非霍奇金淋巴瘤的防控提供科学依据。方法 利用2019年全球疾病负担数据库江苏省非霍奇金淋巴瘤的发病数、发病率、死亡数、死亡率、伤残调整寿命年(disability adjusted life years, DALYs)、DALYs率，分析1990—2019年江苏省非霍奇金淋巴瘤的性别、年龄分布及其变化趋势。结果 2019年江苏省非霍奇金淋巴瘤发病数为7 299例，标化发病率为5.92/10万，死亡数为3 182例，标化死亡率为2.45/10万，DALYs为85 328人年，标化DALYs率为71.79/10万。与1990年相比，各指标均呈上升趋势。不同性别人群非霍奇金淋巴瘤年龄别发病率、死亡率和DALYs率均随年龄的增长而升高，但男性发病率、死亡率和DALYs率高于女性，差异有统计学意义(P<0.05)。结论 1990—2019年江苏省非霍奇金淋巴瘤疾病负担呈加重的趋势，男性和高龄人群是其疾病负担的高危人群，应针对非霍奇金淋巴瘤制定综合防控措施，减轻患者疾病负担。

Disease burden of non-Hodgkin's lymphoma in Jiangsu Province, 1990-2019

Objective To analyze the changes in disease burden of non-Hodgkin's lymphoma in Jiangsu Province from 1990 to 2019, and to provide a scientific basis for prevention and control of non-Hodgkin's lymphoma. Methods We analyzed the gender, age distribution and changing trends of non-Hodgkin's lymphoma in Jiangsu Province during 1990-2019 based on the case number, incidence, mortality, disability-adjusted life years (DALYs), and DALYs rate of non-Hodgkin's lymphoma in Jiangsu Province extracted from the database of the Global Burden of Disease Study 2019. Results In 2019, the number of non-Hodgkin's lymphoma cases in Jiangsu Province was 7,299, and the standardized incidence rate was 5.92/100,000. The number of deaths was 3,182, and the standardized mortality rate 2.45/100,000. The DALYs was 85,328 person-years, and the standardized DALYs rate 71.79/100,000. Compared with those in 1990, all indicators showed an upward trend. The age-specific morbidity, mortality and DALYs rate of non-Hodgkin's lymphoma in different gender populations all increased with age, but the morbidity, mortality and DALYs rate were higher in males than in females, showing statistically significant differences (P<0.05). Conclusion The disease burden of non-Hodgkin's lymphoma in Jiangsu Province from 1990 to 2019 showed an increasing trend, and males and the elderly were the high-risk groups of its disease burden. Comprehensive prevention and control measures against non-Hodgkin's lymphoma should be formulated to reduce disease burden of the patients.